Billy Kelleher (Cork North Central, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

203. To ask the Minister for Health when a re-evaluation will be carried out on the drug Kuvan for persons suffering with PKU under the reimbursement scheme; and if he will make a statement on the matter. [45137/17]

Michael Healy-Rae (Kerry, Independent)
Link to this: Individually | In context | Oireachtas source

217. To ask the Minister for Health his views on the ongoing campaign to get Kuvan available for persons struggling with the metabolic medical condition of PKU (details supplied); and if he will make a statement on the matter. [45221/17]

John Brassil (Kerry, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

218. To ask the Minister for Health if he will request the HSE to reimburse the drug Kuvan used to treat phenylketonuria; and if he will make a statement on the matter. [45227/17]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 203, 217 and 218 together.

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013.

In reaching a decision, the HSE examines all the evidence which may be relevant in its view for the decision and will take into account such expert opinions and recommendations which may have been sought by the HSE, including, for example, advice from the National Centre for Pharmacoeconomics (NCPE).

Sapropterin (Kuvan) was previously considered under the national pricing and reimbursement processes in 2009. At that time, insufficient evidence was available to support the pricing and reimbursement application submitted by Merck Serono.

In December 2015, Merck Serono advised the HSE that the market authorisation for sapropterin was transferring to Biomarin in 2016. The HSE met with the new market authorisation holder in May 2016 and was advised that it would be submitting a health technology assessment dossier in relation to sapropterin.

The NCPE assessment of the new dossier was completed on the 15 September 2017 and the NCPE did not recommend sapropterin for reimbursement as it was not deemed cost effective.

The HSE assessment process is ongoing and the HSE will take into account any relevant expert advice when making its decision, in line with the Health (Pricing and Supply of Medical Goods) Act 2013.